Global Preclinical Oncology Models Market is valued at USD 1335.7 Million in 2024 and is predicted to reach USD 3733.0 Million by 2034, at a 10.9% CAGR during the forecast period 2025-2034.
The rise of immuno-oncology therapy such as T cell therapy, bispecific antibodies, immune checkpoint modulators, and personalized cancer vaccines compels the need for unique preclinical and translational service solution. Recently advances in Immuno-oncology industry with success of CAR-T Therapy boosted the R&D activities in the oncology industry which boost the demand for preclinical oncology models such as humanized models and syngeneic tumor models. The need for predictive approaches and robust preclinical models to minimize translational failures in immuno-oncology is very high. The factors such as early identification of predictive biomarkers, leveraging phenotypic features of models, and the need of rational design of combination therapies drive the growth of the oncology preclinical models market.
The global oncology preclinical models market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Syngeneic Models, Cell Lines Models, Orthotopic Tumor Models, and Others based on application type, the market is segmented into Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Fibrosarcoma, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer and Others.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 1335.7 Million |
| Revenue Forecast In 2034 | USD 3733.0 Million |
| Growth Rate CAGR | CAGR of 10.9% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Model Host Species, By Product, By End User and By Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI Bioresearch Inc, Pharmatest Services, Taconic Biosciences, Inc., and The Jackson Laboratory |
| Customization Scope | Free customization report with the procurement of the report, modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Preclinical Oncology Models Market by Product
Global Preclinical Oncology Models Market Based on Application
By Model Host Species
By End User
Global Preclinical Oncology Models Market Based on Region
Europe Preclinical Oncology Models Market Revenue Outlook
North America Preclinical Oncology Models Market Revenue Outlook
Asia Pacific Preclinical Oncology Models Market Revenue Outlook
Latin America Preclinical Oncology Models Market Revenue Outlook
Middle East & Africa Preclinical Oncology Models Market Revenue Outlook
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Preclinical Oncology Models Market Snapshot
Chapter 4. Global Preclinical Oncology Models Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Technology Advancement in Preclinical Oncology Models
4.9. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Patient-Derived Xenograft Models (PDX)
5.2.2. Cell Line Derived Xenograft Models
5.2.3. Syngeneic Models
5.2.4. Genetically engineered mouse models (GEMMs)
5.2.5. Orthotopic Models
5.2.6. Custom Xenograft and Syngeneic Model
5.2.7. Others
Chapter 6. Preclinical Oncology Models Market Segmentation 2: Application Estimates & Trend Analysis
6.1. Application Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Neuroblastoma
6.2.2. Prostate Cancer
6.2.3. Pancreatic Cancer
6.2.4. Breast Cancer
6.2.5. Colorectal Cancer
Chapter 7. Preclinical Oncology Models Market Segmentation 3: By Model Host Species Estimates & Trend Analysis
7.1. By Model Host Species Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Model Host Species:
7.2.1. Mice
7.2.2. Rats
7.2.3. Rabbits
Chapter 8. Preclinical Oncology Models Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. By End User Analysis & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End User:
8.2.1. Pharmaceutical & Biotechnology Companies
8.2.2. Pharmaceutical & Biotechnology Companies
8.2.3. Pharmaceutical & Biotechnology Companies
Chapter 9. Preclinical Oncology Models Market Segmentation 3: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by Product, 2021-2034
9.1.2. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.1.3. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.1.4. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by By Model Host Species, 2021-2034
9.1.5. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by By End User, 2021-2034
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Preclinical Oncology Models Market revenue (US$ Million) by Product, 2021-2034
9.2.2. Europe Preclinical Oncology Models Market revenue (US$ Million) by Application, 2021-2034
9.2.3. Europe Preclinical Oncology Models Market revenue (US$ Million) by country, 2021-2034
9.2.4. Europe Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, 2021-2034
9.2.5. Europe Preclinical Oncology Models Market revenue (US$ Million) by By End User, 2021-2034
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by Product, 2021-2034
9.3.2. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by Application, 2021-2034
9.3.3. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by country, 2021-2034
9.3.4. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, 2021-2034
9.3.5. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by By End User, 2021-2034
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Preclinical Oncology Models Market revenue (US$ Million) by Product, 2021-2034
9.4.2. Latin America Preclinical Oncology Models Market revenue (US$ Million) by Application, 2021-2034
9.4.3. Latin America Preclinical Oncology Models Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.4.4. Latin America Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, (US$ Million) 2021-2034
9.4.5. Latin America Preclinical Oncology Models Market revenue (US$ Million) by By End User, (US$ Million) 2021-2034
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. MEA
9.5.1. MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by Product, (US$ Million) 2021-2034
9.5.2. MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by Application, (US$ Million) 2021-2034
9.5.3. MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.5.4. MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, (US$ Million) 2021-2034
9.5.5. MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by By End User, (US$ Million) 2021-2034
9.5.5.1. South Africa
9.5.5.2. Rest of MEA
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Aragen Bioscience
10.2.2. vivoPharm Pty. Ltd. (Cancer Genetics, Inc.)
10.2.3. Bioduro
10.2.4. Crown Bioscience Inc.
10.2.5. Charles River
10.2.6. Champion Oncology, Inc.
10.2.7. GenOway S.A.
10.2.8. Hera BioLabs
10.2.9. Pharmatest Services
10.2.10. Taconic Biosciences, Inc.
10.2.11. The Jackson Laboratory